Skip to content 
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey. more
| Time Frame | JNJ | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 3.16% | 1.89% | 1.51% |
| 1-Month Return | 6.82% | 5.68% | 5.65% |
| 3-Month Return | -2.03% | 1.18% | 6.8% |
| 6-Month Return | 4.86% | 15.01% | 18.16% |
| 1-Year Return | 0.26% | 13.5% | 29.33% |
| 3-Year Return | -1.48% | 24.42% | 33.21% |
| 5-Year Return | 27.86% | 80.35% | 100.99% |
| 10-Year Return | 101.82% | 193.83% | 237.54% |
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 82.06B | 82.58B | 93.78B | 94.94B | 85.15B | [{"date":"2019-12-31","value":86.43,"profit":true},{"date":"2020-12-31","value":86.98,"profit":true},{"date":"2021-12-31","value":98.77,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.69,"profit":true}] |
| Cost of Revenue | 27.56B | 28.43B | 29.86B | 31.09B | 26.74B | [{"date":"2019-12-31","value":88.64,"profit":true},{"date":"2020-12-31","value":91.44,"profit":true},{"date":"2021-12-31","value":96.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.01,"profit":true}] |
| Gross Profit | 54.50B | 54.16B | 63.92B | 63.85B | 58.41B | [{"date":"2019-12-31","value":85.27,"profit":true},{"date":"2020-12-31","value":84.73,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.9,"profit":true},{"date":"2023-12-31","value":91.38,"profit":true}] |
| Gross Margin | 66.42% | 65.58% | 68.16% | 67.26% | 68.60% | [{"date":"2019-12-31","value":96.82,"profit":true},{"date":"2020-12-31","value":95.6,"profit":true},{"date":"2021-12-31","value":99.37,"profit":true},{"date":"2022-12-31","value":98.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Expenses | 33.53B | 34.24B | 39.37B | 40.15B | 36.56B | [{"date":"2019-12-31","value":83.52,"profit":true},{"date":"2020-12-31","value":85.29,"profit":true},{"date":"2021-12-31","value":98.06,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.06,"profit":true}] |
| Operating Income | 21.01B | 19.82B | 24.42B | 23.92B | 21.85B | [{"date":"2019-12-31","value":86.04,"profit":true},{"date":"2020-12-31","value":81.19,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.95,"profit":true},{"date":"2023-12-31","value":89.5,"profit":true}] |
| Total Non-Operating Income/Expense | (3.64B) | (3.42B) | (1.77B) | (1.98B) | (6.30B) | [{"date":"2019-12-31","value":-364200000000,"profit":false},{"date":"2020-12-31","value":-341700000000,"profit":false},{"date":"2021-12-31","value":-177100000000,"profit":false},{"date":"2022-12-31","value":-197800000000,"profit":false},{"date":"2023-12-31","value":-630200000000,"profit":false}] |
| Pre-Tax Income | 17.33B | 16.50B | 22.78B | 21.73B | 15.06B | [{"date":"2019-12-31","value":76.08,"profit":true},{"date":"2020-12-31","value":72.43,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.39,"profit":true},{"date":"2023-12-31","value":66.13,"profit":true}] |
| Income Taxes | 2.21B | 1.78B | 1.90B | 3.78B | 1.74B | [{"date":"2019-12-31","value":58.38,"profit":true},{"date":"2020-12-31","value":47.12,"profit":true},{"date":"2021-12-31","value":50.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.88,"profit":true}] |
| Income After Taxes | 15.12B | 14.71B | 20.88B | 17.94B | 13.33B | [{"date":"2019-12-31","value":72.42,"profit":true},{"date":"2020-12-31","value":70.48,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.93,"profit":true},{"date":"2023-12-31","value":63.83,"profit":true}] |
| Income From Continuous Operations | 15.12B | 14.71B | 20.88B | 17.94B | 13.33B | [{"date":"2019-12-31","value":72.42,"profit":true},{"date":"2020-12-31","value":70.48,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":85.93,"profit":true},{"date":"2023-12-31","value":63.83,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
| Net Income | 15.12B | 14.71B | 20.88B | 17.94B | 35.15B | [{"date":"2019-12-31","value":43.01,"profit":true},{"date":"2020-12-31","value":41.86,"profit":true},{"date":"2021-12-31","value":59.39,"profit":true},{"date":"2022-12-31","value":51.04,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| EPS (Diluted) | 8.68 | 8.03 | 9.80 | 10.16 | 10.43 | [{"date":"2019-12-31","value":83.22,"profit":true},{"date":"2020-12-31","value":76.99,"profit":true},{"date":"2021-12-31","value":93.96,"profit":true},{"date":"2022-12-31","value":97.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| JNJ | |
|---|---|
| Cash Ratio | 0.54 |
| Current Ratio | 1.17 |
| Quick Ratio | 0.94 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| JNJ | |
|---|---|
| ROA (LTM) | 8.01% |
| ROE (LTM) | 24.24% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| JNJ | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.59 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.41 |
| Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 2.46 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| JNJ | |
|---|---|
| Trailing PE | 22.92 |
| Forward PE | 13.85 |
| P/S (TTM) | 4.17 |
| P/B | 5.17 |
| Price/FCF | 130 |
| EV/R | 4.25 |
| EV/Ebitda | 15.52 |
| PEG | 0.04 |
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology company specializing in the development of bispecific antibodies for immune-mediated diseases. The deal, valued at $850 million in cash, also includes potential additional milestone payments. This acquisition marks a significant expansion of Johnson & Johnson’s immunology portfolio, […]
Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment. Additionally, these businesses range from consumer staple giants to aerospace titans and healthcare juggernauts. They provide a fundamental combination of operational efficiency, strategic vision, and market supremacy. The first demonstrates its durability and innovative capability in the healthcare industry with a balanced expansion plan spanning both innovative areas. Meanwhile, its steady rise in organic sales and volume expansion demonstrates the second one’s capacity to handle market swings and hold onto market share. Moreover, within the aerospace industry, the third one’s healthy order book and backlog demonstrate ongoing demand for its commercial aircraft. Similarly, the fourth one boasts financial indicators and outstanding success in obtaining foreign orders. Further, the fifth one is positioned as a strong force in the pharmaceutical industry thanks to its operational competence and leadership in therapeutic areas.
With the market rally broadening out, value sectors are beginning to catch a bid. Healthcare deserves consideration as one of the value sectors presenting some bargains in this overheating market. As of this writing, the healthcare sector has increased by 7.0% year-to-date ( YTD ). Although that’s a decent return, it pales in comparison to the 15% gain for technology and the 20% gain in communication services. This underperformance presents a catchup opportunity for healthcare. Moreover, the sector is trading at 19 times the next twelve-month earnings compared to the S&P 500’s 20.6 times. Fundamentally, the growth outlook for the entire sector is excellent. According to the Centers for Medicare & Medicaid Services ( CMS ), healthcare spending will grow 5.4% annually between 2022 and 2031. Thus, expect a demand boom for drugs, hospital services and medical insurance. So, let’s highlight some cheap healthcare stocks to buy with substantial upside. Tenet Healthcare (THC) Source: Shutterstock The market isn’t giving Tenet Healthcare (NYSE: THC ) credit for its transformation.
The rapid advancements in artificial intelligence (AI) and automation have led to a surge in interest in robotics stocks. However, investors should be cautious about investing in this sector in 2024. Many robotics companies are facing significant challenges that could negatively impact their performance and lead to a strong bear case for selling these stocks. This has led to my list of robotics and automation stocks to sell. One major concern is the oversaturation of the market. As more companies enter the robotics space and competition intensifies, participants suffer reduced profit margins and slower growth rates. Additionally, many of these companies are trading at high valuations that do not reflect their underlying fundamentals, making them vulnerable to significant price corrections. Another issue is the uncertainty surrounding the adoption of robotics technology. While there has been progress in sectors like manufacturing and healthcare, the widespread integration of robotics in consumer goods and services has been slower than anticipated.
REDWOOD CITY, Calif., May 16, 2024 /PRNewswire/ -- Proteologix, Inc., a privately-held biotechnology company focused on bispecific antibodies for immune-mediated diseases, today announced that it has entered into a definitive agreement to be acquired by Johnson & Johnson for $850 million…
Too often spinoff stocks don’t perform well out of the gate. Because an investor bought the business of the parent company, he doesn’t care too much about whatever side project is being shed. When the spinoff stock shows up in his account, he sells it and banks the “free” cash. However, investing legend Joel Greenblatt says spinoffs are actually a great buying opportunity. In his classic investing book, “ You Can Be a Stock Market Genius ,” Greenblatt says because the discarded unit was never able to be properly valued inside the larger corporation, once free it can devote appropriate resources to grow the business. It also helps investors more accurately value the business. Below are three spinoffs that occurred within the past year. Let’s see whether the market is appropriately valuing these businesses and whether they are stock spinoffs to buy now. Solventum (SOLV) Source: JPstock / Shutterstock.com One of the most recent spinoffs completed, Solventum (NYSE: SOLV ) is the healthcare business of industrial conglomerate 3M (NYSE: MMM ) that was unleashed on Apr. 1.
NEW YORK (AP) — The Dow Jones Industrial Average just topped 40,000 for the first time, the latest pop in what’s been a surprisingly good year for Wall Street. But just like New Year’s represents an arbitrary point in time in the Earth’s revolution around the sun, such milestones for the Dow don’t mean that much inherently. For one, with just 30 companies, the Dow represents a tiny slice of Corporate America. For another, almost no one’s 401(k) account sees its performance depend on the Dow, which has become more of a relic used for historical comparisons. Here’s a look at what the Dow is, how it got here and how its use among investors is on the wane: WHAT IS THE DOW? It’s a measure of 30 established, well-known companies. These stocks are sometimes known as “blue chips,” which are supposed to be on the steadier and safer side of Wall Street. WHAT’S IN THE DOW? Not just industrial companies like Caterpillar and Honeywell, despite the name. The roster has changed many times since the Dow began in 1896 as the U.S. economy has transformed.
This book was published by David Elias in 1999 and he predicted the Dow Jones Industrial Average would "roar through the 40,000 level by the year 2016" (and specifically June 2, 2016). He was off by 50% on the timeline and the 2000-2009 period was a rough one, but he was on the right side of the market. I almost never look at the Dow Jones Industrial Average because it''s a relic that''s price weighted and only contains 30 stocks. Here are the 30 stocks in the DJIA: 3M Company (MMM) American Express (AXP) Amgen (AMGN) Apple (AAPL) Boeing (BA) Caterpillar (CAT) Chevron (CVX) Cisco Systems (CSCO) The Coca-Cola Company (KO) The Walt Disney Company (DIS) Dow Inc. (DOW) Goldman Sachs (GS) Home Depot (HD) Honeywell (HON) IBM (IBM) Intel (INTC) Johnson & Johnson (JNJ) JPMorgan Chase (JPM) McDonald''s (MCD) Merck & Co. (MRK) Microsoft (MSFT) Nike (NKE) Procter & Gamble (PG) Salesforce (CRM) The Travelers Companies (TRV) UnitedHealth Group (UNH) Verizon Communications (VZ) Visa (V) Walmart (WMT) The Home Depot (HD) Notably missing are many of the megacap tech stocks including Nvidia and Alphabet.
Johnson & Johnson (JNJ) share price today is $154.65
Yes, Indians can buy shares of Johnson & Johnson (JNJ) on Vested. To buy Johnson & Johnson from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JNJ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Johnson & Johnson (JNJ) via the Vested app. You can start investing in Johnson & Johnson (JNJ) with a minimum investment of $1.
You can invest in shares of Johnson & Johnson (JNJ) via Vested in three simple steps:
The 52-week high price of Johnson & Johnson (JNJ) is $172.01. The 52-week low price of Johnson & Johnson (JNJ) is $142.71.
The price-to-earnings (P/E) ratio of Johnson & Johnson (JNJ) is 10.11
The price-to-book (P/B) ratio of Johnson & Johnson (JNJ) is 5.17
The dividend yield of Johnson & Johnson (JNJ) is 3.21%
The market capitalization of Johnson & Johnson (JNJ) is $371.86B
The stock symbol (or ticker) of Johnson & Johnson is JNJ
Link copied 
